A novel oxaliplatin derivative, Ht-2, triggers mitochondrion-dependent apoptosis in human colon cancer cells

Apoptosis

Volumn 20, Issue 1, 2015, Pages 83-91

  Xing, Yingying ^a   Bao, Weiwei ^a   Fan, Xiaobo ^a   Liu, Kunmei ^a   Li, Xiaokang ^a   Xi, Tao ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Antioxidant; Oxaliplatin derivative; Platinum(II) compound; Reactive oxygen species

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; COPPER ZINC SUPEROXIDE DISMUTASE; CYTOCHROME C; HT 2; OXALIPLATIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HT-2 OXALIPLATIN COMPOUND; PLATINUM COMPLEX;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL COUNTING; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; DRUG MECHANISM; FLUORESCENCE MICROSCOPY; HCT116 CELL LINE; HUMAN; HUMAN CELL; IC50; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL PERMEABILITY; PRIORITY JOURNAL; S PHASE CELL CYCLE CHECKPOINT; TRANSMISSION ELECTRON MICROSCOPY; UMBILICAL VEIN ENDOTHELIAL CELL; CHEMISTRY; COLONIC NEOPLASMS; DRUG EFFECTS; METABOLISM; MITOCHONDRION; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; HUMANS; INHIBITORY CONCENTRATION 50; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; ORGANOPLATINUM COMPOUNDS; REACTIVE OXYGEN SPECIES; S PHASE CELL CYCLE CHECKPOINTS;

EID: 84922079532     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-014-1044-6     Document Type: Article

References (25)

1. Wheate NJ, Walker S, Craig GE, Oun R (2010) The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans 39:8113-8127
2. Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozencweig M, Young RC, Muggia FM (1979) Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep 63:1527-1531
3. Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC (1997) Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 57:850-856
4. Montana AM, Batalla C (2009) The rational design of anticancer platinum complexes: the importance of the structure-activity relationship. Curr Med Chem 16:2235-2260
5. Kelland LR (2000) Preclinical perspectives on platinum resistance. Drugs 59(Suppl 4):1-8 discussion 37-38
6. Gao C, Gou S, Fang L, Zhao J (2011) Design, synthesis and in vitro cytotoxicity of novel dinuclear platinum(II) complexes. Bioorg Med Chem Lett 21:1763-1766
7. Yin R, Gou S, Liu X, Lou L (2011) Antitumor activities and interaction with DNA of oxaliplatin-type platinum complexes with linear or branched alkoxyacetates as leaving groups. J Inorg Biochem 105:1095-1101
8. Gao C, Xu G, Gou S (2011) Antitumor dinuclear platinum(II) complexes derived from a novel chiral ligand. Bioorg Med Chem Lett 21:6386-6388
9. Gou S, Sun Y (2010) Trans-N-alkyl-substituted 1,2-diaminocyclohexane platinum ligand (II) complex and its preparation method, CN 102234295 B (in Chinese)
10. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271-279
11. Kerr JF, Wyllie AH, Currie AR (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239-257
12. Wang H, Joseph JA (1999) Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radic Biol Med 27:612-616
13. Hua S, Zhang H, Song Y, Li R, Liu J, Wang Y et al (2012) High expression of Mfn1 promotes early development of bovine SCNT embryos: improvement of mitochondrial membrane potential and oxidative metabolism. Mitochondrion 12:320-327
14. Yao Y, Zhang YW, Sun LG, Liu B, Bao YL, Lin H et al (2012) Juglanthraquinone C, a novel natural compound derived from Juglans mandshurica Maxim, induces S phase arrest and apoptosis in HepG2 cells. Apoptosis 17:832-841
15. Yin R, Bao W, Xing Y, Xi T, Gou S (2012) MiR-19b-1 inhibits angiogenesis by blocking cell cycle progression of endothelial cells. Biochem Biophys Res Commun 417:771-776
16. Fokkema E, Groen HJ, Helder MN, de Vries EG, Meijer C (2002) JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin. Biochem Pharmacol 63:1989-1996
17. Gatti L, Supino R, Perego P, Pavesi R, Caserini C, Carenini N et al (2002) Apoptosis and growth arrest induced by platinum compounds in U2-OS cells reflect a specific DNA damage recognition associated with a different p53-mediated response. Cell Death Differ 9:1352-1359
18. Manic S, Gatti L, Carenini N, Fumagalli G, Zunino F, Perego P (2003) Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Curr Cancer Drug Targets 3:21-29
19. Roos WP, Kaina B (2006) DNA damage-induced cell death by apoptosis. Trends Mol Med 12:440-450
20. Green DR, Reed JC (1998) Mitochondria and apoptosis. Science 281:1309-1312
21. Perlman H, Zhang X, Chen MW, Walsh K, Buttyan R (1999) An elevated bax/bcl-2 ratio corresponds with the onset of prostate epithelial cell apoptosis. Cell Death Differ 6:48-54
22. Raisova M, Hossini AM, Eberle J, Riebeling C, Wieder T, Sturm I et al (2001) The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol 117:333-340
23. Sayers TJ (2011) Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother 60:1173-1180
24. Engels IH, Stepczynska A, Stroh C, Lauber K, Berg C, Schwenzer R et al (2000) Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. Oncogene 19:4563-4573
25. Mlakar SJ, Osredkar J, Prezelj J, Marc J (2012) Antioxidant enzymes GSR, SOD1, SOD2, and CAT gene variants and bone mineral density values in postmenopausal women: a genetic association analysis. Menopause 19:368-376